



Entry into the European phase (EPO as designated or elected Office)

To the European Patent Office

European application number	
PCT application number	PCT/NO2007/000069
PCT publication number	
Applicant's or representative's reference	PMSTest1200-08
International Filing Date	17.05.2007
International Search Authority (ISA)	XN
International Preliminary Examination Authority (IPEA)	EP
1. Applicant	
Indications concerning the applicant(s) are contained in the international publication or were recorded by the International Bureau after the international publication.	<input checked="" type="checkbox"/>
Changes which have not yet been recorded by the International Bureau are set out here:	<input type="checkbox"/>
2. Representative	
3. Authorisation	
An individual authorisation is attached.	<input type="checkbox"/>
A general authorisation has been registered under No:	<input type="checkbox"/>
A general authorisation has been filed, but not yet registered.	<input type="checkbox"/>
The authorisation filed with the EPO as PCT receiving Office expressly includes the European phase.	<input type="checkbox"/>
4. Request for examination	
Examination of the application under Art. 94 EPC is hereby requested. The examination fee is being (has been, will be) paid.	<input checked="" type="checkbox"/>
Request for examination in an admissible non-EPO language:	<input checked="" type="checkbox"/>
	Med dette begjæres prøving av patentsøknaden i henhold til Art. 94
The applicant waives his right to be asked under Rule 70(2) EPC whether he wishes to proceed further with the application.	<input type="checkbox"/>
5. Copies	
Additional copies of the documents cited in the supplementary European search report are requested.	<input type="checkbox"/>
Number of additional sets of copies	
6. Documents intended for proceedings before the EPO	
6.1 Proceedings before the EPO as designated Office (PCT I) are to be based on the following documents:	
the application documents published by the International Bureau (with all claims, description and drawings), where applicable with amended claims under Art. 19 PCT	<input type="checkbox"/>
unless replaced by the amendments attached.	<input type="checkbox"/>
<i>Where necessary, clarifications should be attached as 'Other documents'</i>	
6.2 Proceedings before the EPO as elected Office (PCT II) are to be based on the following documents:	
the documents on which the international preliminary examination report is based, including any annexes	<input type="checkbox"/>
unless replaced by the amendments attached.	<input checked="" type="checkbox"/>
<i>Where necessary, clarifications should be attached as 'Other documents'</i>	
If the EPO as International Preliminary Examining Authority has been supplied with test reports, these may be used as the basis of proceedings before the EPO.	<input checked="" type="checkbox"/>
7. Translations	
Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below:	<input type="checkbox"/>

** In proceedings before the EPO as designated or elected Office (PCT I + II):*

Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material

Translation of the priority application(s) (to be filed only at the EPO's request, Rule 53(3) EPC)

It is hereby declared that the international application as originally filed is a complete translation of the previous application (Rule 53(3) EPC)

** In addition, in proceedings before the EPO as designated Office (PCT I):*

Translation of amended claims and any statement under Art. 19 PCT, if the claims as amended are to form the basis for the proceedings before the EPO (see Section 6).

** In addition, in proceedings before the EPO as elected Office (PCT II):*

Translation of annexes to the international preliminary examination report

8. Biological material

The invention uses and/or relates to biological material deposited under Rule 31 EPC.

The particulars referred to in Rule 31(1)(c) EPC (if not yet known, the depositary institution and the identification reference(s)) [number, symbols, etc.] of the depositor) are given in the international publication or in the translation submitted in Section 7 on:

page(s) / line(s)

The receipt(s) of deposit issued by the depositary institution is (are) enclosed.

will be filed later.

Waiver of the right to an undertaking from the requester pursuant to Rule 33(2) EPC attached.

9. Nucleotide and amino acid sequences

The items pursuant to Rules 5.2 and 13ter PCT, Rules 30 and 163(3) EPC are already with the EPO.

The sequence listing is attached in PDF format.

The sequence listing does not include matter which goes beyond the content of the application as filed.

The sequence listing data is also attached in computer-readable form in accordance with WIPO Standard 25.

The sequence listing data in computer-readable form in accordance with WIPO Standard 25 is identical to the sequence listing in PDF format.

10. Designation fees

All the contracting states party to the EPC at the time of filing of the international patent application and designated in the international application are deemed to be designated (see Article 79(1) EPC).

AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV
MC MT NL PL PT RO SE SI SK TR

10.1 It is currently intended to pay fewer than seven designation fees, for the following contracting states:

10.2 If contracting states are indicated in Section 10.1, it is agreed that for the contracting states not thus indicated no communication under Rule 112(1) EPC be issued and further processing be excluded.

11. Extension of the European patent

This application is deemed to be a request to extend the European patent application and the European patent granted in respect of it to all the non-contracting states to the EPC designated in the international application and with which extension agreements are in force on the date on which the international application is filed. However, the extension only takes effect if the prescribed extension fee is paid.

It is currently intended to pay the extension fee for the following states:

Note: Under the automatic debiting procedure, extension fees will only be debited for states indicated here, unless the EPO is instructed otherwise before expiry of the period for payment.

12. List of enclosed documents			
	Description of document	Original file name	Assigned file name
1	AMABST	amended_abst.pdf	AMABST.pdf
2	AMCLMS	amended_clms.pdf	AMCLMS.pdf
3	AMDESC	amended_desc.pdf	AMDESC.pdf
4	AMDRAW	amended_draw.pdf	AMDRAW.pdf

13. Mode of payment: Debit from deposit account Currency The European Patent Office is hereby authorised, to debit from the deposit account with the EPO any fees and costs indicated on the fees page. Deposit account number Account holder		<input checked="" type="checkbox"/> EUR 28490000 EPO test account
--	--	--

14. Any refunds should be made to the following EPO deposit account:	<input type="checkbox"/>
---	--------------------------

15. Fees				
		Factor/reducti on applied	Fee schedule	Amount to be paid
15-1	002 Fee for (supplementary) European search for applications filed on/after 01.07.2005	-890	1 050.00	160.00
15-2	005 Designation fee Designated states: AT, BE, BG, CH&LI, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR	7	85.00	595.00
15-3	006 Examination fee (EP and Euro-PCT with supplementary European search report)	0.4	1 405.00	562.00
15-4	015 Claims fee(s) (Rules 45(1), 162(1) EPC)	0	200.00	0.00
15-5	020 Filing fee - entry EP phase (Rule 159(1)(c) EPC)	1	100.00	100.00
15-6	033 Renewal fee for the 3rd year	1	400.00	400.00
Total:			EUR	1 817.00

16. Annotations	
------------------------	--